PepGen (PEPG) Income towards Parent Company (2021 - 2026)

PepGen (PEPG) reported Income towards Parent Company of -$17.8 million for Q1 2026, up 41.19% on a YoY basis from -$12.6 million in Q1 2025, and up 2.89% sequentially from -$18.3 million in Q4 2025.

PepGen (PEPG) Income towards Parent Company (2021 - 2026) Analysis & Trends

PepGen (PEPG) has 6 years of Income towards Parent Company data on file, last reported at -$17.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Income towards Parent Company rose 41.19% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$77.2 million (up 24.92% YoY), and the FY2025 full-year result was -$89.7 million, changed 0.36% from the prior year.
  • Income towards Parent Company improved to -$17.8 million in Q1 2026, from -$18.3 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$16.3 million in Q1 2023 to a low of -$46.3 million in Q4 2022.
  • A 5-year average of -$22.2 million and a median of -$19.4 million in 2023 frame the typical range for Income towards Parent Company.
  • Across the five-year window, Income towards Parent Company slumped 4709.24% in 2022 and surged 58.06% in 2023, its largest moves.
  • Tracing PEPG's Income towards Parent Company over 5 years: stood at -$46.3 million in 2022, then surged by 58.06% to -$19.4 million in 2023, then declined by 17.7% to -$22.9 million in 2024, then gained by 19.98% to -$18.3 million in 2025, then grew by 2.89% to -$17.8 million in 2026.
  • Business Quant data shows PEPG's Income towards Parent Company at -$17.8 million in Q1 2026, -$18.3 million in Q4 2025, and -$18.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,538.84 Bn 65,538.56 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
4 BeOne Medicines 469.46 Bn 464.67 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.69 Bn 115.45 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.41 Bn 61.65 Bn 3.31 Bn
7 Belite Bio 62.84 Bn 62.84 Bn -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn
10 PepGen 132.31 Mn 132.31 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.76 Mn
Dec 31, 2025 -18.29 Mn
Sep 30, 2025 -18.03 Mn
Jun 30, 2025 -23.09 Mn
Mar 31, 2025 -30.20 Mn
Dec 31, 2024 -22.86 Mn
Sep 30, 2024 -21.38 Mn
Jun 30, 2024 -28.34 Mn
Mar 31, 2024 -18.02 Mn
Dec 31, 2023 -19.42 Mn
Sep 30, 2023 -23.29 Mn
Jun 30, 2023 -19.52 Mn
Mar 31, 2023 -16.32 Mn
Dec 31, 2022 -46.31 Mn
Sep 30, 2022 -18.63 Mn
Jun 30, 2022 -17.30 Mn
Mar 31, 2022 -18.25 Mn
Dec 31, 2021 -963,000.00
Sep 30, 2021 -8.11 Mn
Jun 30, 2021 -5.39 Mn